copanlisib for injection

A drug used to treat adults with follicular lymphoma that came back after treatment with at least two other systemic therapies. It is also being studied in the treatment of other types of cancer. Copanlisib hydrochloride blocks certain proteins, which may help keep cancer cells from growing and may kill them. It is a type of kinase inhibitor. Also called Aliqopa. US Brand Name(s): Aliqopa. FDA Approved: Yes

Are you looking for or in search of FDA approved “copanlisib for injection in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for Blood Disorders. Need Access of “copanlisib for injection” get in touch with our healthcare professional.

copanlisib for injection price in Latin America, Russia, UK and USA.
copanlisib for injection

Copanlisib is a drug which is approved by US FDA for the treatment of adult patients experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies. Copanlisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms expressed in malignant B-cells. It has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines.

Use in Cancer
Copanlisib hydrochloride is approved to treat:

Follicular lymphoma that has relapsed. It is used in adults who have received at least two other systemic treatments. This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that copanlisib hydrochloride provides a clinical benefit in these patients.Copanlisib hydrochloride is also being studied in the treatment of other types of cancer.

    copanlisib for injection

    Contact No.

    Call us
    +91 11 4350 7259

    Emergency Contact
    +91 93139 48015


    Visit us anytime
    F-90/1 , Okhla Industrial Area,
    Phase -1 , New Delhi. India

    Send us an email